AstraZeneca's Ultomiris hits primary endpoint in rare kidney disease trialProactive Investors • 04/21/26
AstraZeneca's Ultomiris reduces urine protein in late-stage trial of rare kidney diseaseReuters • 04/21/26
Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPDBusiness Wire • 04/20/26
Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to KnowZacks Investment Research • 04/15/26
AstraZeneca faces China headwinds and key drug launches as two banks back 20% upsideProactive Investors • 04/10/26
AZN vs. MRK: Which Oncology Stock Offers Better Investment Potential?Zacks Investment Research • 04/09/26
AstraZeneca's liver cancer breakthrough puts Imfinzi on course to become a super-blockbuster drugProactive Investors • 04/07/26
AstraZeneca: The Bigger Picture Remains Solid Growth Amidst Improving Margins And ReturnsSeeking Alpha • 04/05/26
Trump threatens 100% tariff on US drug makers that don't strike deals to lower pricesThe Guardian • 04/02/26
AstraZeneca's liver cancer therapy combo slows disease progression in late-stage trialReuters • 04/02/26
US bank sees AstraZeneca HPP drug data as supportive of $2.6bn forecast with upside to $4.4bn despite mixed trial resultsProactive Investors • 04/01/26
Tozorakimab trial success hands AstraZeneca a crucial edge in the race to crack COPD's hardest-to-treat patientsProactive Investors • 03/30/26
Astrazeneca (AZN) Advances While Market Declines: Some Information for InvestorsZacks Investment Research • 03/27/26